Novo Nordisk stock edges lower as heart drug trials are halted and obesity data impresses

Published on 09/07/2026 at 15:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock is trading slightly lower after the company halted two heart drug studies while simultaneously reporting promising Phase 3 semaglutide results in young children, leaving investors to weigh growth in obesity treatments against setbacks in cardiovascular ambitions.

Modernes nordisches Forschungszentrum, Glasfassade, Skandinavisches Architekturdesign — Novo Nordisk A/S (DK0062498333): nordisches Forschungszentrum mit Glasfassade und klaren skandinavischen Linien, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) is trading slightly down on September 7, 2026 as investors digest a mixed clinical news flow, combining the halt of additional heart-drug trials with new late-stage data showing that semaglutide significantly reduced obesity rates in children aged 6 to under 12 years over 68 weeks.Reuters Market data for Novo Nordisk as of September 7, 2026 show the shares around 298.62 Danish kroner, only marginally below the prior close of 298.90 Danish kroner, highlighting that the clinical headlines are prompting a measured rather than dramatic share-price reaction.Zonebourse

Heart drug trials halted and investor reaction

According to a report on September 7, 2026, Novo Nordisk announced that it has halted two additional clinical trials of its experimental cardiovascular drug ziltivekimab due to lack of efficacy, adding to earlier setbacks in this program and raising questions about the company’s ability to expand meaningfully beyond its core obesity and diabetes franchises.Reuters In the same coverage, the decision is framed as a further dent in Novo Nordisk’s efforts to build a broader cardiovascular portfolio, reinforcing that near-term growth will continue to depend heavily on GLP-1-based obesity and diabetes treatments rather than new heart-disease indications.Reuters

Real-time quotes on September 7, 2026 from a European trading snapshot show Novo Nordisk shares at 298.62 Danish kroner, a decline of just 0.09 percent from the previous closing price of 298.90 Danish kroner, while the year-to-date performance remains positive at about 2.21 percent and the stock is still down roughly 8.12 percent from the start of the year’s high-water mark.Zonebourse For investors, this mild intraday move suggests that although the ziltivekimab halt is a clear negative for diversification, the market continues to assign substantial value to the company’s established obesity and diabetes pipeline, which is supported by ongoing data and regulatory progress.

STEP Young Phase 3 trial highlights pediatric obesity opportunity

On September 7, 2026, Novo Nordisk released the first results from the STEP Young Phase 3 trial, a study evaluating once-weekly semaglutide combined with reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity.Globenewswire The company stated that after 68 weeks of treatment, 40.4 percent of the children receiving semaglutide were no longer classified as having obesity, assuming full adherence to the regimen, underscoring a substantial clinical impact in a patient group that historically has limited pharmacological options.Reuters

As described in the same reporting, this result indicates that semaglutide can transform the weight-status profile for nearly half of treated children over the study period, meaningfully more than would be expected with lifestyle measures alone.Reuters For comparison, the trial data imply a marked improvement versus baseline obesity prevalence in this cohort over the 68-week period, positioning the pediatric extension of semaglutide-based therapy as a potentially important new revenue stream layered on top of adult indications where Wegovy and related brands already generate significant sales.

Analyst and market context around Novo Nordisk stock

Equity-market commentary on September 7, 2026 highlights that Novo Nordisk shares are trading close to the consensus analyst price target, with an average target of approximately 309.73 Danish kroner compared with a recent closing price of 298.90 Danish kroner, implying around 3.62 percent upside from that reference level.Zonebourse This modest gap suggests that, at current valuations, analysts see limited near-term price appreciation unless new catalysts emerge, and that the mixed clinical signals from heart failure and obesity trials are likely to be weighed carefully in upcoming research updates.

In intra-day trading snapshots, Novo Nordisk’s share price around 298.62 Danish kroner on September 7, 2026 reflects the tension between disappointment over halted cardiovascular trials and enthusiasm about the STEP Young data, with the stock neither rallying strongly nor selling off sharply on the day.Zonebourse For investors assessing the risk-reward balance, the quantified comparison between the current price and the average target of 309.73 Danish kroner provides a concrete benchmark: the stock trades only a few percent below where the analyst community, on average, expects it to be, which leaves limited room for multiple expansion without fresh earnings or pipeline surprises.

Key product: semaglutide and Wegovy franchise

At the center of Novo Nordisk’s story is semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, which already addresses adult obesity and has now been tested in the STEP Young pediatric trial.Reuters The new data showing that 40.4 percent of treated children were no longer classified as having obesity after 68 weeks reinforces the notion that the Wegovy franchise may extend into younger populations, adding incremental volume growth on top of the existing adult indications and broadening the addressable market over time.Reuters

Stock price snapshot and investor takeaway

Based on the European trading overview dated September 7, 2026, Novo Nordisk stock recently closed at 298.90 Danish kroner and was quoted at 298.62 Danish kroner during the latest session, with the current level sitting below an average analyst target of 309.73 Danish kroner but still supported by positive year-to-date returns.Zonebourse For investors, the combination of halted ziltivekimab heart trials and strong STEP Young semaglutide data underscores a familiar theme: Novo Nordisk’s valuation and share-price trajectory continue to hinge primarily on the durability and expansion of its obesity and diabetes franchise, while diversification into new cardiovascular indications remains a work in progress that carries both scientific and commercial risk.